Publications found:
73,128
Sort by:
INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!
US$ 140.00
... both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI). Despite limited clinical data in hand, PC and in vitro ... read our report released on 13th February 2013 on INFI titled “IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!”
February 2013
8 pages
Therapeutic Class Report Overview - Hemophilia
US$ 2,000.00
Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used ...
February 2013
47 pages
Global and China Hemodialysis Industry Report, 2012-2013
US$ 2,200.00
... Science and Technology, etc. Given the huge potential in Chinese hemodialysis market, several listed companies have tapped into the field, ... landscape, import & export and development prediction of Chinese hemodialysis industry; Global and China hemodialysis equipment market segments and competition pattern ...
February 2013
91 pages
Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)
US$ 800.00
... filled syringes a fast-growing alternative to vials for many parenteral drugs such as vaccines, anticoagulants and therapeutic proteins. The report titled “Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)” provides an in-depth analysis of the global prefilled syringes market with major focus on biggest healthcare markets of U.S and Europe. It also ...
February 2013
78 pages
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
US$ 495.00
... Pharma do to maximise the credibility and visibility of its products? Overview The Path to Product Inclusion in Clinical Guidelines: Strategies for Success If you ... defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical
February 2013
49 pages
CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion
US$ 140.00
With our conservative view on Revlimid – opportunity in EU (no approval in NDMM and Maintenance setting), reimbursement in China, and patent challenges; we expect net product sales’ CAGR (2013-17) of 17% (vs. CELG’s guidance: 19%) including risk adjusted late stage pipeline. We are positive on upcoming ...
January 2013
6 pages
ROCHE, Confidence building up on next gen. Rituxan (GA101)
US$ 90.00
Roche seems to be on track of delivering sustainable growth as it announced ... forward. With Perjeta and T-DM1 as well shaping up well, Roche is on a strong ground to sustain its revenues from Herceptin ... expected to reach the market in 2016, but by then, Roche would have GA101 on the market which would fend off ...
January 2013
3 pages
DISHMAN, Worry on Cash Flow Continues
US$ 140.00
... visibility of free cash flow generation, we continue to remain concerned about the fate of highly levered (operating and financial) business model of Dishman. The fact ... land clearly signifies that company is not generating sufficient free cash flow to service its debt. As the proposed sale of SEZ land has ...
January 2013
6 pages
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
US$ 2,000.00
... (CELG) M&A in Kinase Inhibitors in the last 5 years Related Milestones/catalysts in 2013-14 Combination Studies – PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological ...
January 2013
62 pages
GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory
US$ 140.00
nitial sales of newly added HIV products – Complera/ Eviplera (L, truvada + rilpivirine), Stribild (L in US, ... products contributed to the impressive 4Q12/FY13 results of Gilead. Positive data of Sofosbuvir (PMI, PhIII) in ... Through life cycle management of products for HIV, late stage HCV drugs and focus on ...
January 2013
8 pages
PHARMACYCLICS - Ibrutinib - Promising to Deliver More
US$ 140.00
... that there is meaningful upside on positive PhIII data and approval of Ibrutinib (PCI-32765, PhIII, BTK inhibitor, partnered with JNJ, PhIII ... of time, and iv) Patient tolerability including lack of bone marrow damage. Ibrutinib is a best-in-class among leukemia drugs, showed durable efficacy in Tx-naïve (TN) ...
January 2013
14 pages
Competitor Analysis: Enzyme Replacement Therapies
US$ 403.00
... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...
January 2013
74 pages
Closing the Loop: delivering real-world commercial benefit from closed-loop marketing
US$ 595.00
Your step-by-step guide to adapting to real time change. Over the past decade, closed loop marketing (CLM) has been a buzzword in pharma marketing ... actionable by themselves. This is where most companies are stuck in the closed-loop marketing cycle.” Marc Valdiviezo, former director of multichannel marketing, Pfizer.
January 2013
59 pages
Digital Health Quarterly 1Q 2013 2Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2013
17 pages
Digital Health Quarterly 2Q 2013 3Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2013
17 pages
Digital Health Quarterly 3Q 2013 4Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2013
17 pages
Digital Health Quarterly 4Q 2012 1Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2013
19 pages
Research Report on China's High-end Medical Treatment Industry, 2013-2017
US$ 2,800.00
... are on the rather low level. The rich and foreigners in China attach importance to quality and privacy of medical services and they are ... is easier to create characteristics through equipment, technologies and services, China's high-end medical services are concentrated in these fields. However, investments in ...
December 2012
50 pages
Italy Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 2,880.00
... report contains 142 pages, 15 tables and presents a comprehensive analysis of the Italian flow cytometry market, including: Major issues pertaining to the Italian ... . Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
142 pages
Japan Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 3,600.00
... report contain 142 pages, 15 tables and presents a comprehensive analysis of the Japanese flow cytometry market, including: Major issues pertaining to the Japanese ... . Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
142 pages
Spain Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 2,880.00
... report contains 140 pages, 15 tables and presents a comprehensive analysis of the Spanish flow cytometry market, including: Major issues pertaining to the Spanish ... . Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
140 pages
UK Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 2,880.00
This report contains 146 pages, 15 tables and presents a comprehensive analysis of the UK flow cytometry market, including: Major issues pertaining to the ... systems. Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
146 pages
US Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 4,720.00
This report contains 147 pages, 17 tables and presents a comprehensive analysis of the US flow cytometry market, including: Major issues pertaining to the ... systems. Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
147 pages
Tele-Health Carts, Servers, and Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
US$ 3,700.00
WinterGreen Research announces that it has a new study on Tele-Health Carts, Servers, and Monitoring Market Shares and Forecasts, Worldwide, 2012 ... anticipated to grow rapidly worldwide as efficiencies of scale are realized for monitoring and treating people with chronic conditions in a more standardized manner ...
December 2012
366 pages
Competitor Analysis: Toll-like Receptor (TLR) Agonists & Antagonists
US$ 910.00
... description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small ... with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role ...
December 2012
178 pages
India Cosmetic Surgery Market Outlook 2016
US$ 700.00
... cosmetic surgeries market inIndia. Research report “India Cosmetic Surgery Market Outlook 2016” gives comprehensive overview on the following aspects related to Cosmetic surgery segment in India. Cosmetic surgery Market Potential Treatment Cost Patient Profile & Preferred Cosmetic ...
December 2012
70 pages
Global Hearing Instruments Market Report: 2012 Edition
US$ 800.00
... hearing loss. The hearing loss is treated by hearing instruments which include two categories: Hearing Aid and Hearing Implant. The present report offers a comprehensive analysis of the worldwide hearing instrument ... Korea. The competition in the global hearing instrument market is intense with few large players ...
November 2012
53 pages
Brisotl-Myers Squibb - Eliquis Approved for SPAF in Europe – Waiting for decision with FDA
US$ 90.00
... and PFE announced the long awaited approval of Eliquis for stroke prevention in atrial fibrillation ... US approval, for which the PDUFA data has been set for 17th March 2013. . We foresee Eliquis clearly ... demonstrated in the ROCKET-AF trial. We expect Eliquis to cannibalize Pradaxa sales initially, while extensive ...
November 2012
2 pages
NATCO PHARMA– Outperform, Great Result - More to Come
US$ 140.00
Natco Pharma’s Q2 FY13 result was much ahead of our expectation on sales and EBITDA largely ... our expectation as Natco wrote off `61m as payment to SMS pharma over its old litigation. The company already launched Sunitinib in India, however, expects ...
November 2012
8 pages
Celgene - ABRAXANE + Pipeline Drugs = Long Term Growth!
US$ 140.00
... Revlimid’s label expansion in 1st line RRMM and as maintenance therapy in EU, Celgene (CELG) 3Q12 earnings highlighted growth of Revlimid globally on both a YoY ... data from ABRAXANE trials in melanoma and pancreatic cancer……please read our report released on 11th Nov. 2012, titled, 'ABRAXANE + Pipeline Drugs = ...
November 2012
7 pages
CIPLA– Market Perform, Great Result But Not Completely Sustainable
US$ 140.00
Q2FY13 result was ahead of our estimates largely on account of higher than ... base. On a longer term basis, we do not remain enthused about Cipla’s inhaler opportunity in Europe as it has lost the first mover advantage ... estimate by 7-8%. We upgrade our target price to Rs.360 but retain our Market Perform rating.
November 2012
9 pages
DISHMAN – Underperform, Management Accepts the Limitations of Pure Play CRAMS
US$ 140.00
... we have continuously mentioned as the biggest problem for Dishman. Management now intends enter the global generic business so ... as to utilize the idle capacity. However, the management is probably late in realizing this as it will ... and also retain our Underperform rating on Dishman with target price of Rs.47
November 2012
6 pages
Nuclear Medicine: Market Research Report
US$ 4,950.00
This report analyzes the worldwide markets for Nuclear Medicine in US$ Million by the following Product Segments: Gamma Cameras, and PET Scanners. The ... ., Toshiba Medical Systems Corporation, and Toshiba America Medical Systems, Inc. Market data and analytics are derived from primary and secondary research. ...
November 2012
302 pages
France Healthcare Market: 2012 Sector Report
US$ 600.00
... the government of France, the healthcare market in France will continue to grow for the years to come. The report titled “France Healthcare Sector: Sector Report” analyzes the healthcare industry of France in terms of the functioning of the healthcare ...
November 2012
40 pages
The Rise of Health Outcome Liaison Teams
US$ 645.00
... help pharma companies answer these critical questions. REPORT OVERVIEW The Rise of Health Outcome Liaison Teams At last – a practical guide to building your ... HOL strategy. This comprehensive report explains what is driving the rise of HOLs globally, and provides detailed accounts of how major pharma ...
November 2012
86 pages
